Particularly in hepatocellular carcinoma and male thyroid cancer, ASF1B was proposed as a potential target and immunological marker for tumor therapy (Ouyang et al. 2021; Zhang et al. 2022; Qiu et al. 2022). Here, ASF1B is linked to hepatocellular carcinoma.